Answers are grounded in this paper and cite their sources.
In 2024, Fat Studies published my article on glucagon-like peptide agonist medications (GLP-1s) and antifatness (Oswald 2024). In that article, I briefly outlined a number of moral, ethical, and so...
No takes yet. Share an insight, caveat, or question.
Flora Oswald (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: